nach oben

Erschienen in:

01.02.2015 | Original Article

Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia

verfasst von: Heidrun Boztug, Marco Zecca, Karl-Walter Sykora, Paul Veys, Arjan Lankester, Mary Slatter, Roderick Skinner, Jacek Wachowiak, Ulrike Pötschger, Evgenia Glogova, Christina Peters, on behalf of the EBMT paediatric diseases working party

Erschienen in: Annals of Hematology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Standard myeloablative conditioning regimens for children with acute lymphoblastic leukaemia are based on total body irradiation (TBI). However, TBI causes profound short-term and long-term side effects, provoking the necessity for alternative regimens. Treosulfan combines a potent immunosuppressive and antileukaemic effect with myeloablative activity and low toxicity profile. We retrospectively studied toxicity and outcome of 71 paediatric patients with acute lymphoblastic leukaemia (ALL) undergoing haematopoietic stem cell transplantation (HSCT) following treosulfan-based conditioning aiming to identify risk factors for treatment failure and dose-depending outcome differences. Early regimen-related toxicity was low. No case of veno-occlusive disease was reported. There was no association of toxicity with age or number of HSCT. Event-free survival (EFS) of infants was significantly better compared to older children. Overall survival (OS) at 3 years was 51 % and not significantly influenced by number of HSCT (first HSCT 54 %, ≥second HSCT 44 %, p = 0.71). In multivariate analysis, OS and EFS were significantly worse for patients transplanted without complete remission (p = 0.04 and 0.004). Treatment-related mortality was low at 14 %. We conclude that treosulfan-based conditioning is a safe and efficacious approach for paediatric ALL.

Peters C, Schrauder A, Schrappe M et al (2005) Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplant 35(Suppl 1):S9–11PubMedCrossRef

Schrappe M, Reiter A, Zimmermann M et al (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14:2205–2222PubMedCrossRef

Pulsipher MA, Peters C, Pui CH (2011) High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant 17:S137–148PubMedCentralPubMedCrossRef

Eckert C, Henze G, Seeger K et al (2013) Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 31:2736–2742PubMedCrossRef

Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C (2008) Allogeneic hematopoietic SCT in children with all: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 41(Suppl 2):S71–74PubMedCrossRef

Balduzzi A, Valsecchi MG, Uderzo C et al (2005) Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366:635–642PubMedCrossRef

Balduzzi A, Valsecchi MG, Silvestri D et al (2002) Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant 29:93–100PubMedCrossRef

Linsenmeier C, Thoennessen D, Negretti L et al (2010) Total body irradiation (TBI) in pediatric patients. a single-center experience after 30 years of low-dose rate irradiation. Strahlenther Onkol 186:614–620PubMedCrossRef

Ricardi U, Filippi AR, Biasin E et al (2009) Late toxicity in children undergoing hematopoietic stem cell transplantation with TBI-containing conditioning regimens for hematological malignancies. Strahlenther Onkol 185(Suppl 2):17–20PubMedCrossRef

10.

Bresters D, van Gils IC, Kollen WJ et al (2010) High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant 45:79–85PubMedCrossRef

11.

Marks DI, Forman SJ, Blume KG et al (2006) A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 12:438–453PubMedCrossRef

12.

Davies SM, Ramsay NK, Klein JP et al (2000) Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 18:340–347PubMed

13.

Baron F, Storb R, Storer BE et al (2006) Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 24:4150–4157PubMedCrossRef

14.

Pulsipher MA, Boucher KM, Wall D et al (2009) Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the pediatric blood and marrow transplant consortium study ONC0313. Blood 114:1429–1436PubMedCrossRef

15.

Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S (2003) Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 32:543–548PubMedCrossRef

16.

Del Toro G, Satwani P, Harrison L et al (2004) A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 33:613–622PubMedCrossRef

17.

Scheulen ME, Hilger RA, Oberhoff C et al (2000) Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6:4209–4216PubMed

18.

Glowka FK, Karazniewicz-Lada M, Grund G, Wrobel T, Wachowiak J (2008) Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant 42(2):S67–70PubMedCrossRef

19.

Wachowiak J, Sykora KW, Cornish J et al (2011) Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant 46:1510–1518PubMedCrossRef

20.

Fichtner I, Becker M, Baumgart J (2003) Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 39:801–807PubMedCrossRef

21.

van Pel M, van Breugel DW, Vos W, Ploemacher RE, Boog CJ (2003) Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant 32:15–22PubMedCrossRef

22.

Poetschger U, Sykora K-W, Zecca M et al (2012) Meta-analysis on treosulfan for conditioning in children and adolescents before hematopoietic stem cell transplantation. Bone Marrow Transplant 47:S37

23.

Glucksberg H, Storb R, Fefer A et al (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295–304PubMedCrossRef

24.

Klein JP, Rizzo JD, Zhang MJ, Keiding N (2001) Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling. Bone Marrow Transplant 28:1001–1011PubMedCrossRef

25.

Klein JP, Rizzo JD, Zhang MJ, Keiding N (2001) Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 28:909–915PubMedCrossRef

26.

Fine JG, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 9:496–509CrossRef

27.

Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef

28.

Hosmer D, Lemeshow S (2000) Applied logistic regression. Wiley, New York, 2nd editionCrossRef

29.

Levy JM. Tello T. Giller R. et al. Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. Pediatr Blood Cancer 2012.

30.

Vassal G, Deroussent A, Hartmann O et al (1990) Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50:6203–6207PubMed

31.

Carpenter PA, Marshall GM, Giri N, Vowels MR, Russell SJ (1996) Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 18:489–494PubMed

32.

Eom KS, Shin SH, Yoon JH et al (2013) Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol 88:634–641PubMedCrossRef

33.

Satwani P, Morris E, Bradley MB, Bhatia M, van de Ven C, Cairo MS (2008) Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 50:1–8PubMedCrossRef

34.

Bartelink IH, Bredius RG, Belitser SV et al (2009) Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 15:231–241PubMedCrossRef

35.

Ansari M. Theoret Y. Rezgui MA. et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit 2013

36.

Munkelt D, Koehl U, Kloess S et al (2008) Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol 62:821–830PubMedCrossRef

37.

Hilgendorf I, Wolff D, Gromke T et al (2011) Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. Bone Marrow Transplant 46:502–509PubMedCrossRef

38.

Nemecek ER, Guthrie KA, Sorror ML et al (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 17:341–350PubMedCentralPubMedCrossRef

39.

Danylesko I, Shimoni A, Nagler A (2012) Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplant 47:5–14PubMedCrossRef

40.

Casper J, Wolff D, Knauf W et al (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 28:3344–3351PubMedCrossRef

41.

Corker E, Astwood E, Williams J, Vora A (2012) Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia. Br J Haematol 159:104–106PubMedCrossRef

42.

Slatter MA, Rao K, Amrolia P et al (2011) Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 117:4367–4375PubMedCrossRef

43.

Beier R, Schulz A, Honig M et al (2013) Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience. Bone Marrow Transplant 48:491–501PubMedCrossRef

44.

Bernardo ME, Piras E, Vacca A et al (2012) Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 120:473–476PubMedCrossRef

45.

Law J, Cowan MJ, Dvorak CC et al (2012) Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant 18:1656–1663PubMedCrossRef

46.

Heli U, Eeva J, Anne N, Tapani R, Liisa V (2012) Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine. Eur J Haematol 88:87–88PubMedCrossRef

47.

Greystoke B, Bonanomi S, Carr TF et al (2008) Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 142:257–262PubMedCrossRef

48.

Kato M, Takahashi Y, Tomizawa D et al (2013) Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia. Biol Blood Marrow Transplant 19:1690–1694PubMedCrossRef

49.

Vettenranta K (2008) Current European practice in pediatric myeloablative conditioning. Bone Marrow Transplant 41(Suppl 2):S14–17PubMedCrossRef

50.

Bartelink IH. van Reij EM. Gerhardt CE. et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant 2013.

51.

Kato M, Horikoshi Y, Okamoto Y et al (2012) Second allogeneic hematopoietic SCT for relapsed all in children. Bone Marrow Transplant 47:1307–1311PubMedCrossRef

52.

Mann G, Attarbaschi A, Schrappe M et al (2010) Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 116:2644–2650PubMedCrossRef

53.

Pui C-H, Gaynon PS, Boyett JM et al (2002) Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909–1915PubMedCrossRef

54.

Pieters R, Schrappe M, De Lorenzo P et al (2007) A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370:240–250PubMedCrossRef

55.

Cutting R, Mirelman A, Vora A (2008) Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. Br J Haematol 143:748–751PubMedCrossRef

56.

Knechtli CJ, Goulden NJ, Hancock JP et al (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92:4072–4079PubMed

57.

Duerst RE, Horan JT, Liesveld JL et al (2000) Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. Bone Marrow Transplant 25:489–494PubMedCrossRef

58.

Balis FM, Poplack DG (1989) Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 11:74–86PubMedCrossRef

Titel: Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia
verfasst von: Heidrun Boztug
Marco Zecca
Karl-Walter Sykora
Paul Veys
Arjan Lankester
Mary Slatter
Roderick Skinner
Jacek Wachowiak
Ulrike Pötschger
Evgenia Glogova
Christina Peters
on behalf of the EBMT paediatric diseases working party
Publikationsdatum: 01.02.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 2/2015
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-014-2196-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

HFE-related hemochromatosis risk mutations in Latvian population

Unusual relapse of an angioimmunoblastic T cell lymphoma 11 years after initial manifestation

Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients

Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation

Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia